Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Based on the overwhelming positive response to this survey and the large number of patients
being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a
trial that will randomize patients who have disease stability to stop treatment at 1 year or
continue treatment until disease progression. The investigators anticipate that the results
of this study will answer questions regarding the optimal duration of treatment. therapy.